The risk of Parkinson's disease in type 1 Gaucher disease
- PMID: 20177787
- PMCID: PMC2887303
- DOI: 10.1007/s10545-010-9055-0
The risk of Parkinson's disease in type 1 Gaucher disease
Abstract
In Gaucher disease, defective lysosomal glucocerebrosidase due to mutations in the GBA1 gene results in lysosomal accumulation of glucocerebroside in mononuclear phagocytes and a multisystemic phenotype. Observations of occurrence of Parkinson's disease in some patients with non-neuronopathic type 1 Gaucher disease (GD1) and their first degree relatives has led to the identification of GBA1 heterozygous mutations as a genetic risk factor for idiopathic Parkinson's disease (PD). However, the magnitude of risk of PD in patients with known GD1 has not been determined, and it is not known whether GD1/PD represents a specific sub-phenotype of GD1 with distinctive genotype/phenotype characteristics. We estimated the risk of PD in a cohort of 444 consecutively evaluated patients with GD1 compared to that in the general population. Eleven patients developed parkinsonian syndrome during a 12-year follow-up period. The adjusted life-time risk ratio of PD in GD1 compared to that in the general population was 21.4 [95% confidence interval (95% CI) 10.7-38.3], with a higher risk in men compared to women. In our cohort, GD1/Parkinson's disease phenotype (GD1/PD) was characterized by higher GD1 severity score, due to higher incidence of avascular osteonecrosis. The clinical spectrum of PD varied from mild to potentially life-threatening disease. All but one patient with GD1/PD phenotype had at least one N370S GBA1 allele. In conclusion, compared to the general population, patients with GD1 have an almost 20-fold increased life-time risk of developing PD.
Conflict of interest statement
Competing interest: None declared.
Similar articles
-
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.Mov Disord. 2023 May;38(5):899-903. doi: 10.1002/mds.29342. Epub 2023 Mar 3. Mov Disord. 2023. PMID: 36869417 Free PMC article.
-
Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease.Mov Disord. 2011 Jun;26(7):1341-3. doi: 10.1002/mds.23595. Epub 2011 Apr 5. Mov Disord. 2011. PMID: 21469198
-
Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.J Clin Neurosci. 2016 Jun;28:185-6. doi: 10.1016/j.jocn.2015.12.004. Epub 2016 Feb 5. J Clin Neurosci. 2016. PMID: 26857292 Free PMC article.
-
Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.Adv Drug Deliv Rev. 2022 Aug;187:114402. doi: 10.1016/j.addr.2022.114402. Epub 2022 Jun 25. Adv Drug Deliv Rev. 2022. PMID: 35764179 Review.
-
The relationship between glucocerebrosidase mutations and Parkinson disease.J Neurochem. 2016 Oct;139 Suppl 1(Suppl Suppl 1):77-90. doi: 10.1111/jnc.13385. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26860875 Free PMC article. Review.
Cited by
-
Cerebrospinal fluid biomarkers in Parkinson disease.Nat Rev Neurol. 2013 Mar;9(3):131-40. doi: 10.1038/nrneurol.2013.10. Epub 2013 Feb 19. Nat Rev Neurol. 2013. PMID: 23419373 Review.
-
A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease.JIMD Rep. 2012;3:53-7. doi: 10.1007/8904_2011_48. Epub 2011 Sep 20. JIMD Rep. 2012. PMID: 23430873 Free PMC article.
-
Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson's Disease.Cells. 2020 Aug 26;9(9):1966. doi: 10.3390/cells9091966. Cells. 2020. PMID: 32858884 Free PMC article.
-
Bacterial β-Glucosidase Reveals the Structural and Functional Basis of Genetic Defects in Human Glucocerebrosidase 2 (GBA2).ACS Chem Biol. 2016 Jul 15;11(7):1891-900. doi: 10.1021/acschembio.6b00192. Epub 2016 May 6. ACS Chem Biol. 2016. PMID: 27115290 Free PMC article.
-
Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson's disease and Dementia with Lewy bodies.bioRxiv [Preprint]. 2025 Jan 2:2024.10.23.619548. doi: 10.1101/2024.10.23.619548. bioRxiv. 2025. PMID: 39484386 Free PMC article. Preprint.
References
-
- Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972–1977. - PubMed
-
- Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology. 2003;61:99–101. - PubMed
-
- Beutler E. Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl. 2006;95:103–109. - PubMed
-
- Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med. 1998;158:1754–1760. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical